AstraZeneca year-to-date and Q3 2019 results
AstraZeneca PLC 24 October 2019 07:00 BST Year-to-date and Q3 2019 results Patients to benefit from further pipeline progress; sales-growth momentum driving operating leverage Year-to-date Product Sales growth of 13% (17% at CER[1]) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). The third quarter again saw all three therapy areas and every sales region produce encouraging performances, including: · The continued performance of new medicines[2],[ ]with sales growth in the quarter of 62% (+64% at CER) to $2,707m, including new-medicine growth